The Highly Anticipated “Triple Agonist” Weight Loss Med Is Almost Here—What Doctors Say About It
This Medication May Lead to 28.7% Weight Loss Jarren Vink Eli Lilly just announced phase 3 clinical trial…
Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of…
Common antidepressant helps reduce some men’s domestic violence, ReINVEST trial finds
What if a common anti-depressant could help stop some angry, impulsive men from committing domestic violence? That question…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
Digital tools and chatbots can expand genetic counseling for young cancer survivors
A groundbreaking new study from the Alliance for Clinical Trials in Oncology aims to test whether digital tools…
Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation
A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical…
Scientists map the genes behind diet and dementia risk
Scientists reveal a new genetic resource from the MIND diet trial, opening the door to precision nutrition strategies…
Breakthrough gene therapy reverses genetic deafness across age groups
Using gene therapy to treat hereditary deafness is safe and effective in both children and adults, according to…